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Abstract
Background and aim: Damage to small nociceptive fibres may contribute to painful diabetic 
neuropathy. We aimed to compare large and small nerve fibre measurements together with skin 
biopsy and corneal confocal microscopy (CCM) in patients with type 1 diabetes and painful or 
painless diabetic neuropathy.
Methods: We have assessed the McGill pain questionnaire, neuropathy disability score (NDS), 
vibration perception threshold (VPT), warm and cold sensation thresholds (WST, CST), 
electrophysiology, corneal confocal microscopy (CCM) and skin biopsy in participants with type 1 
diabetes and painful (n=41) or painless (n=50) diabetic neuropathy and control subjects (n=50). 
Results: The duration of diabetes, BMI, HbA1c, blood pressure and lipid profile did not differ 
between subjects with painful and painless neuropathy. Neuropathy disability score, and vibration 
perception threshold were higher and sural nerve conduction velocity was lower but sural nerve 
amplitude, peroneal nerve amplitude and conduction velocity and cold and warm sensation 
thresholds did not differ between patients with painful compared to painless diabetic neuropathy. 
However, intra-epidermal nerve fibre density, corneal nerve fibre density, corneal nerve branch 
density and corneal nerve fibre length were significantly lower in subjects with painful compared 
to painless diabetic neuropathy. 
Conclusions: There is evidence of more severe neuropathy, particularly small fibre damage in the 
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Introduction
Approximately 20% of patients with diabetic peripheral neuropathy (DPN) develop painful 
neuropathy which is associated with significant morbidity and reduced quality of life 1. The 
efficacy of current therapies is highly variable 2,3, which may in part reflect diverse etiological 
mechanisms operating at the peripheral nociceptor, spinal and supraspinal levels in painful DPN 4. 
It has been suggested that phenotyping patients based on their symptom complex and identifying 
the primary site and mechanism of their symptoms may allow a more tailored therapeutic 
approach and improved response to treatment 5. However, sensory testing, skin punch biopsy and 
brain imaging have been deemed to have insufficient evidence to support their use as biomarkers 
in pain clinical trials 6. Furthermore, a retrospective analysis of 7 clinical trials showed a limited 
impact of sensory phenotyping on predicting the efficacy of drugs to relieve neuropathic pain 7. 
Given that painful diabetic neuropathy is considered to arise from dysfunction and damage to 
nociceptive C-fibres and autonomic fibres 8,9, it is no surprise that standard neurophysiology does 
not differentiate diabetic patients with painful compared to painless neuropathy 10. Indeed, whilst 
neurophysiological parameters such as the F-wave and H-reflex identify patients with sub-clinical 
diabetic neuropathy, they cannot differentiate patients with and without painful neuropathy 11,12. 
However, a recent metanalysis has shown a greater abnormality in heat pain thresholds in patients 
with painful compared to painless diabetic neuropathy 13. But, a skin biopsy study demonstrated 
no difference in IENFD in patients with and without painful neuropathy 14. Similarly, another 
detailed immunohistochemical skin biopsy study found no difference in IENFD, but patients with 
painful diabetic neuropathy had an increased density of dermal peptidergic fibers containing SP 
and CGRP compared to patients with painless DPN and healthy controls 15. We have previously 
shown a reduction in intraepidermal nerve fibre length in patients with painful compared to 
painless diabetic neuropathy 16. A recent study has shown increased axonal regeneration and 
swelling 17, whilst another study has shown no relationship between the severity of axonal 
swelling 18 and painful diabetic neuropathy. Furthermore, exercise reduced painful neuropathic 
symptoms but was associated with an increase in IENF branch density 19.
Corneal confocal microscopy (CCM) is a rapid, non-invasive technique, which can be used to 
image and quantify small fibre pathology 20 and is comparable to IENFD for the diagnosis of 
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length in patients with painful compared to painless diabetic neuropathy 16 and more recently we 
have shown a reduction in central and inferior whorl corneal nerve fibre length in patients with 
painful diabetic neuropathy 24. Furthermore, in a recent study from China there was greater corneal 
nerve fibre damage in diabetic patients with painful compared to painless diabetic neuropathy 25. 
In the present study, we have compared detailed measures of large and small fibre function 
together with skin biopsy and CCM in a large cohort of patients with type 1 diabetes and painful 
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Research Design and Methods
Study Participants
91 participants with type 1 diabetes mellitus and 50 age-matched healthy control subjects were 
studied. The study was approved by the North Manchester Research Ethics committee and written 
informed consent was obtained from all participants. This research adhered to the tenets of the 
Declaration of Helsinki. Patients with a history of any systemic disease apart from diabetes 
associated with neuropathy were excluded from the study. In addition, patients with any history of 
systemic or ocular diseases associated with corneal involvement were excluded from the study. 
Clinical and peripheral neuropathy assessments
All participants underwent a complete medical history and an assessment of body mass index 
(BMI), blood pressure, glycated haemoglobin (HbA1c), cholesterol, LDL, HDL and triglycerides. 
Symptoms of neuropathy were assessed using the neuropathy symptom profile (NSP) and short 
form McGill pain questionnaire (SF-MPQ) 26.
Detailed assessment of neuropathy included the neuropathy disability score (NDS), vibration 
perception threshold (VPT) on the hallux of both feet using a Neurothesiometer (Horwell, 
Scientific Laboratory Supplies, Wilford, Nottingham, UK), cold and warm sensation threshold 
(CST & WST); and cold and heat induced pain threshold (CIP & HIP) using a TSA-II 
NeuroSensory Analyser (Medoc Ltd., Ramat-Yishai, Israel) on the dorsolateral aspect of the left 
foot. A Dantec “Keypoint” system (Dantec Dynamics Ltd, Bristol, UK) was used to measure sural 
nerve action potential amplitude (SNAP) and conduction velocity (SNCV) and peroneal nerve 
action potential amplitude (PMNAP) and conduction velocity (PMNCV).
Skin biopsy and IENFD assessment
Two 3-mm punch skin biopsies were taken from the dorsum of the dominant foot, 2 cm above the 
second metatarsal head under local anaesthesia (1% lidocaine). The biopsies were immediately 
fixed in 4% paraformaldehyde, cryoprotected in graded solutions of sucrose, frozen and cut on a 
cryomicrotome (HM450, Microm International, Germany). Six 50 micrometre sections per biopsy 
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fibres were demonstrated using SG chromogen (Vector Laboratories, Peterborough, U.K.) 27. 
IENFD (no./mm) was quantified in accordance with established criteria and expressed as a number 
of nerve fibres per millimetre length of epidermis 28. 
Corneal confocal microscopy
The central cornea of all study participants was scanned using a laser IVCCM (Heidelberg Retinal 
Tomograph III Rostock Cornea Module (HRT III RCM); Heidelberg Engineering GmbH, 
Heidelberg, Germany) 29. The examination was performed according to our previously published 
protocol, by highly experienced optometrists and took approximately 5 minutes for both eyes of 
each participant 30. Six images (3 from each eye) from the corneal sub-basal nerve plexus were 
exported and used for image analysis. Two experienced examiners analysed all the images 
manually using CCMetrics (MA Dabbah; Imaging Science and Biomedical Engineering, 
University of Manchester, Manchester, UK), while being masked from the outcome of medical 
and peripheral neuropathy assessments. Corneal nerve morphological parameters including 
corneal nerve fibre density (CNFD), the number of main nerve fibres/mm2; corneal nerve branch 
density (CNBD), the number of branch points on the main nerves/mm2; corneal nerve fibre length 
(CNFL), the total length of nerves mm/mm2; and corneal nerve fibre tortuosity (CNFT), the 
tortuosity coefficient of main nerves (TC) were measured for each image and the average of the 
results from 6 images was used for data analysis.
Corneal sensation was measured in the centre of the cornea using non-contact corneal 
aesthesiometry (NCCA) (Glasgow Caledonian University, Glasgow, Scotland, UK) 31. 
Study definition of painful neuropathy
All 91 patients with type 1 diabetes were confirmed to have diabetic neuropathy based on an 
abnormality in at least two out of five neurological measures including IENFD (<3.3), CNFD 
(<24.4), CST (<23.8), VPT (>16.5) or PMNCV (<40) defined by results lying 2SD out with the 
mean of control subjects. Patients were divided into two groups based on the SF-MPQ & McGill 
pain index (PI) with a score >1/5 considered to have painful diabetic neuropathy and those with a 
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IBM SPSS v19.0 (Chicago, IL, USA) for Windows was used to compute the results. Analysis 
included descriptive and frequency statistics and all data presented as Mean ± SD. Shapiro-Wilk 
test and Q-Q plots were used to evaluate whether the data were normally distributed or not. To 
evaluate the difference between the two groups, the Independent sample T test (Mann-Whitney U 
test for non-parametric) and to evaluate the difference among the groups, One-way ANOVA with 
Bonferroni adjustment were used.
Results
Demographic and clinical findings
Ninety-one patients with type 1 diabetes mellitus, 41 with painful neuropathy and 50 with painless 
neuropathy and 50 age-matched controls were studied. There was no difference in age, gender, 
ethnicity, smoking, alcohol consumption, BMI, lipid profile, blood pressure and HbA1c, but 
height was significantly lower (P=0.02) in patients with painful compared to painless diabetic 
neuropathy (Table 1).
Neuropathy assessments
SNCV, SNAP, PMNCV, PMNAP, CST and IENFD were significantly (P<0.01) lower and NSP, 
NDS, VPT and WST were significantly higher (P<0.01) in patients with type 1 diabetes compared 
to control subjects. 
NSP (P=0.0001), NDS (P=0.003) and VPT (P=0.001) were higher and SNCV (P=0.009) was 
lower in patients with painful compared to painless neuropathy. IENFD was significantly lower 
(P=0.02) in patients with painful compared to painless neuropathy (Figure 1). There was no 
correlation between NDS, VPT, quantitative sensory testing and neurophysiology with the severity 
of painful neuropathic symptoms using the McGill visual analogue index (Table 2).
Corneal sensation and nerve fibre pathology
The corneal sensation threshold was significantly higher in patients with painful neuropathy 
compared to control subjects (P<0.001) and painless diabetic neuropathy (P=0.003). CNFD, 
CNBD and CNFL were significantly lower (P<0.001) in patients with type 1 diabetes compared to 
healthy controls and CNFD (P=0.005), CNFL (P=0.01) and CNBD (P=0.05) were significantly 
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was significantly higher (P=0.03) in patients with painless neuropathy compared to controls but 
there was no difference between patients with painful and painless diabetic neuropathy. There was 
no correlation between corneal nerve parameters and the severity of neuropathic pain based on the 
McGill visual analogue index. 
Discussion
The present study confirms our previous studies demonstrating that CCM can identify neuropathy 
in patients with diabetes 32-34. Small fibre neuropathy is considered to underlie neuropathic pain 35, 
however, symptom assessment tools 36 as opposed to measures of small fibre dysfunction or 
damage are advocated in the diagnosis of neuropathic pain 37. This is because there is controversy 
as to whether specific features of small fibre pathology in skin biopsies 38,39  may be related to 
painful neuropathy 17,18,40,41. 
We demonstrate a more severe neuropathy in patients with painful neuropathy, which is consistent 
with our data from a large population based study 1 and from two recent detailed phenotyping 
studies 42. Most neurophysiological measures and thermal thresholds did not differ between 
patients with painful and painless diabetic neuropathy, in agreement with previous data 9,16. 
However, there was evidence of a greater reduction in IENFD, CNFD, CNBD and CNFL in 
patients with painful compared to painless diabetic neuropathy 16,43. The lower corneal nerve 
branch density, suggests lower nerve regeneration, which contrasts with the results of a recent 
study showing increased axonal regeneration and axonal swelling in patients with painful diabetic 
neuropathy 17. 
Identifying small fibre pathology may help in the diagnosis and identification of patients who may 
respond optimally to a particular therapy. Indeed in two randomized placebo controlled studies the 
best response to treatment with oxcarbazepine 44 and lignocaine 5% patch 45 was achieved in those 
patients with an irritable nociceptor phenotype. We have recently shown that patients with altered 
rate dependent depression, indicating reduced spinal inhibition and those with a reduction in 
corneal nerve fibre density may respond optimally to therapies such as duloxetine 43. 
This is a cross sectional study which prevents us from concluding a causal relationship between 
small fibre damage in the skin and cornea in patients with painful diabetic neuropathy. The study 
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the majority of patients with type 2 diabetes. Although, greater corneal nerve fibre damage has 
been shown in patients with type 2 diabetes and painful compared to painless neuropathy 25. In 
addition, previous studies have assessed patients with type 1 and type 2 diabetes and shown 
greater small nerve fibre damage in painful compared to painless neuropathy 9,16,24.
Corneal confocal microscopy represents a rapid non-invasive ophthalmic imaging technique to 
objectively quantify small fibre pathology and differentiate patients with painful from painless 
diabetic neuropathy.
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Figure 1. Representative examples of 50 µm sections from skin biopsies immunostained for 
PGP9.5 In healthy control (A), a diabetic patient with painless neuropathy (B) and a diabetic 
patient with painful neuropathy (C). Healthy control (A) shows numerous long branching 
intraepidermal nerve fibres reaching upper levels of the epidermis (red arrow heads) and well-
developed sub-epidermal nerve plexus (yellow arrow heads). Biopsy from diabetic patient with 
painless neuropathy shows scant but well developed intraepidermal nerve fibres compared to a 
biopsy from diabetic patient with painful neuropathy (C) showing scant short intraepidermal nerve 
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Figure 2. CCM images of corneal sub basal nerve plexus in a healthy control, patient with type 1 
diabetes in painless and painful neuropathy (Red arrows: main nerve, yellow arrows: branches).
Figure 3. Corneal nerve fibre density (CNFD) (A), corneal nerve branch density (CNBD) (B) and 
corneal nerve fibre length (CNFL) (C) and Intra epidermal nerve fibre density (D) was reduced 
significantly in diabetic patients compared to control subjects and was further reduced in diabetic 
patients with painful compared to painless diabetic neuropathy.
Table 1. Demographic and clinical findings in healthy controls and patients with type 1 diabetes 
with and without painful neuropathy. Data are presented as Mean ± SD. All symbols indicate 
statistically significant difference, * P<0.01 compared to controls and # P<0.05 compared to 
patients with painless neuropathy.
Table 2. Neuropathy symptoms, deficits, quantitative sensory testing, neurophysiology, skin 
biopsy, corneal sensitivity and confocal microscopy in healthy controls and patients with type 1 
diabetes with painful and painless diabetic neuropathy. Data are presented as Mean ± SD. All 
symbols indicate statistically significant difference, * P<0.01 compared to controls and # P<0.05 
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Type 1 diabetes 
Painful 
Neuropathy 
Number  50 50 41 
Age (years) 51.5±12.7 47.6±14.4 52.7±14.4 
Gender (F/M) 26/24 20/30 24/17 
Ethnicity (Asian/European) 18/32 4/46 3/38 
Duration of diabetes (years) _ 30.8±17.0 33.6±16.1 
Smoking (no per day) 0.7±2.4 1.8±4.9 1.7±5.5 
Alcohol consumption (units per 
week) 
5.1±7.6 5.6±8.1 3.2±5.9 
HbA1c (%) 5.6±0.3 8.2±1.2* 8.5±1.7* 
IFCC (mmol/mol) 37.7±3.6 64.7±18.1* 69.6±18.5* 
BMI (kg/m
2
) 26.7±4.5 26.7±4.1 27.03±4.8 
Height (cm) 166.0±10.7 171.6±9.2* 166.1±9.4
#
 
Waist circumference (cm) 90.3±14.9 92.3±13.5 89.8±18.9 
Cholesterol (mmol/l) 5.0±0.7 4.4±0.9 4.2±0.7 
HDL (mmol/l) 1.6±0.5 1.6±0.4 1.7±0.5 
Triglycerides (mmol/l) 1.4±0.7 1.1±0.6 1.2±0.7 
LDL (mmol/l) 2.7±0.7 2.3±0.9* 2.1±0.4* 







Table 1. Demographic and clinical findings in healthy controls and patients with type 1 
diabetes with and without painful neuropathy. Data are presented as Mean ± SD. All symbols 
indicate statistically significant difference, * P<0.01 compared to controls and # P<0.05 
compared to patients with painless neuropathy. HbA1c – glycated haemoglobin, BMI – body 
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Parameters Control Type 1 diabetes 
Painless 
Type 1 diabetes 
Painful  
McGill VAS (0-10)  0 0.04±0.2 5.51±2.7
*#(P<0.0001)
 
NSP (0-38) 0.3±0.8 1.6±2.9 8.2±6.4
# (P=0.0001)
 
NDS (0-10) 0.6±1.2 2.6±1.4 4.5±2.2
# (P=0.003) 





C) 28.2±2.2 25.3±5.3* 22.3±8.2* 
WST (
˚
C) 36.9±3.1 39.8±3.5* 41.6±4.9* 
CIP (
˚
C) 11.8±9.4 7.3±7.2* 7.4±8.9 
HIP (
˚
C) 44.9±3.2 45.9±3.3 47.3±3.1* 
SNCV (m/s) 50.2±4.5 42.7±6.0* 38.5±7.9
*# (P=0.009)
 
SNAP (µV) 19.4±9.6 9.8±7.7* 6.6±6.8* 
PMNCV (m/s) 48.6±4.1 40.3±7.3* 37.7±8.7* 
PMNAP (mV) 5±2.2 3.7±2.5 2.7±4.1* 
IENFD (no./mm) 9.1±2.9 6.6±4* 4.4±4.2*
#(P=0.02)
 















) 26.1±5.2 19.8±5.6* 15.7±7.8
*# (P=0.01)
 
CNFT (TC) 15.6±3.6 19.2±6.9* 17.5±8.6 
Table 2. Neuropathy symptoms, deficits, quantitative sensory testing, neurophysiology, skin 
biopsy, corneal sensitivity and confocal microscopy in healthy controls and T1DM patients 
with painful and painless diabetic neuropathy. Data are presented as Mean ± SD. All symbols 
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compared to the patients with painless neuropathy. McGill VAS – visual analogue scale, NSP 
– neuropathy symptom profile, NDS – neuropathy disability score, VPT – vibration 
perception threshold, CST – cold sensation threshold, WST – warm perception threshold, CIP 
– cold induced pain threshold, HIP – heat induced pain threshold, SNCV – sural nerve 
conduction velocity, SNAP – sural nerve action potential amplitude, PMNCV – peroneal 
motor nerve conduction velocity, PMNAP – peroneal nerve action potential amplitude, 
IENFD – intra epidermal nerve fibre density, NCCA – non-contact corneal aesthesiometry, 
CNFD – corneal nerve fibre density, CNBD – corneal nerve branch density, CNFL – corneal 
nerve fibre length, CNFT – corneal nerve fibre tortuosity, TC – tortuosity coefficient.  
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